Ditching Delay: GH001’s Instant Impact on Depression

What It Covers

GH Research CEO Vili Valcheva discusses GH001 (mebifotidine), a synthetic five-methoxy-DMT therapy for treatment-resistant depression that shows 57.5% remission rates at day eight versus SPRAVATO's 21% at day 28, with same-day symptom improvement and infrequent dosing averaging four treatments per six months.

Key Questions Answered

• •Ultra-Rapid Treatment Response: GH001 delivers measurable improvement in depressive symptoms within two hours of administration, with patients reporting ability to manage daily tasks and enjoy activities the same day. This contrasts sharply with traditional oral antidepressants requiring four to six weeks to show effect and SPRAVATO's complex eight-week induction requiring twice-weekly then weekly dosing before benefits appear.
• •Superior Clinical Outcomes: Phase 2b data demonstrated 15.5-point placebo-adjusted reduction on MADRS scale with 57.5% remission rate at day eight, compared to SPRAVATO monotherapy achieving 21% remission at day 28. The treatment requires average of four clinic visits over six months, with 97.4% of patients discharge-ready within one hour after final dose, showing no sedation or dissociation at discharge.
• •Simplified Treatment Protocol: GH001 administration involves one to three inhalations during a one to three-hour clinic visit, without mandated psychotherapy sessions. This approach reduces cost, improves scalability, and provides patient choice compared to psychotherapy-integrated protocols. Side effects remain mild to moderate, occurring primarily during the psychoactive phase, eliminating next-day drowsiness and driving restrictions associated with competing treatments.
• •Scheduled Substance Development Challenges: Developing five-methoxy-DMT requires obtaining separate controlled drug licenses for each trial site and each new trial, with regulations varying by state. Planning timelines must account for manufacturing, distribution, and on-site storage rules. GH Research's completion of 80-patient trial across 20-plus sites established operational know-how for managing these regulatory complexities in future pivotal programs.
• •Expansion Potential Beyond TRD: Proof-of-concept data exists for postpartum depression and bipolar disorder type two, with phase 2b showing effectiveness for anxiety symptoms. Scientific community identifies additional applications including PTSD, terminal cancer patients, and chronic pain conditions. The treatment's rapid-acting mechanism and infrequent dosing model positions it for multiple mental health indications once treatment-resistant depression approval establishes the platform.